William Z. Levine, D.D.S.
Cannabis Science and Technology™ is proud to announce the addition of William Z. Levine, D.D.S., to its editorial advisory board.
“We look forward to having Dr. Levine joining the Cannabis Science and Technology™ advisory board,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, the parent company of Cannabis Science and Technology™. “His experience and contributions will be a great asset to our editorial staff as we continue to deliver unprecedented content to our readers.”
Levine is the founder of Izun Pharmaceuticals Corporation, a biopharmaceutical company specializing in botanical medicine. This area of specialty pharma develops pharmaceutical and health care products from plant-based sources. Levine, who received his D.D.S. degree and specialty training in periodontics from Columbia University, initially utilized this background to formulate novel oral care products to treat periodontal disease more effectively. Izun has also developed wound care products, oncology support products, and products targeting women’s health care.
Subsequently, recognizing the Izun expertise in botanicals, Levine applied this knowledge to the cannabis plant and established CannRx. In a short time, CannRx has developed novel targeted formulations, highly effective drug delivery systems specifically designed for cannabis, and completely new extraction systems.
As a member of the advisory board, Levine will work closely with the editorial team and the existing 16 board members to recommend topics, solicit and provide content, and share breaking news and information on the latest happenings in the cannabis industry.
For more information about the Cannabis Science and Technology™ editorial advisory board, click here.
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.